In light of the ACLU versus Myriad Genetics case, David Ewing Duncan at Tech Review asks the age-old question: "Should human DNA be owned?" In the US, Duncan says that an individual's BRCA1 gene cannot be patented, but that Myriad could patent a mutated gene sequence associated with breast cancer. Then, patients' genes could be compared to the patented sequence -- that is what the ACLU and other plaintiffs say is a mistake. Duncan says the complaint is beside the point.